Cargando…

Risk of subsequent primary lymphoma in a cohort of 69,460 five‐year survivors of childhood and adolescent cancer in Europe: The PanCareSurFup study

BACKGROUND: Survivors of Hodgkin lymphoma (HL) are at risk of developing non‐Hodgkin lymphoma (NHL) after treatment; however, the risks of developing subsequent primary lymphomas (SPLs), including HL and NHL, after different types of childhood cancer are unknown. The authors quantified the risk of S...

Descripción completa

Detalles Bibliográficos
Autores principales: Dudley, Isabelle M., Sunguc, Ceren, Heymer, Emma J., Winter, David L., Teepen, Jop C., Belle, Fabiën N., Bárdi, Edit, Bagnasco, Francesca, Gudmundsdottir, Thorgerdur, Skinner, Roderick, Michel, Gisela, Byrne, Julianne, Øfstaas, Hilde, Jankovic, Momcilo, Mazić, Maja Česen, Mader, Luzius, Loonen, Jaqueline, Garwicz, Stanislaw, Wiebe, Thomas, Alessi, Daniela, Allodji, Rodrigue S., Haddy, Nadia, Grabow, Desiree, Kaatsch, Peter, Kaiser, Melanie, Maule, Milena M., Jakab, Zsuzsanna, Gunnes, Maria Winther, Terenziani, Monica, Zaletel, Lorna Zadravec, Kuehni, Claudia E., Haupt, Riccardo, de Vathaire, Florent, Kremer, Leontien C., Lähteenmäki, Päivi M., Winther, Jeanette F., Hjorth, Lars, Hawkins, Michael M., Reulen, Raoul C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099796/
https://www.ncbi.nlm.nih.gov/pubmed/36444554
http://dx.doi.org/10.1002/cncr.34561
_version_ 1785025132096389120
author Dudley, Isabelle M.
Sunguc, Ceren
Heymer, Emma J.
Winter, David L.
Teepen, Jop C.
Belle, Fabiën N.
Bárdi, Edit
Bagnasco, Francesca
Gudmundsdottir, Thorgerdur
Skinner, Roderick
Michel, Gisela
Byrne, Julianne
Øfstaas, Hilde
Jankovic, Momcilo
Mazić, Maja Česen
Mader, Luzius
Loonen, Jaqueline
Garwicz, Stanislaw
Wiebe, Thomas
Alessi, Daniela
Allodji, Rodrigue S.
Haddy, Nadia
Grabow, Desiree
Kaatsch, Peter
Kaiser, Melanie
Maule, Milena M.
Jakab, Zsuzsanna
Gunnes, Maria Winther
Terenziani, Monica
Zaletel, Lorna Zadravec
Kuehni, Claudia E.
Haupt, Riccardo
de Vathaire, Florent
Kremer, Leontien C.
Lähteenmäki, Päivi M.
Winther, Jeanette F.
Hjorth, Lars
Hawkins, Michael M.
Reulen, Raoul C.
author_facet Dudley, Isabelle M.
Sunguc, Ceren
Heymer, Emma J.
Winter, David L.
Teepen, Jop C.
Belle, Fabiën N.
Bárdi, Edit
Bagnasco, Francesca
Gudmundsdottir, Thorgerdur
Skinner, Roderick
Michel, Gisela
Byrne, Julianne
Øfstaas, Hilde
Jankovic, Momcilo
Mazić, Maja Česen
Mader, Luzius
Loonen, Jaqueline
Garwicz, Stanislaw
Wiebe, Thomas
Alessi, Daniela
Allodji, Rodrigue S.
Haddy, Nadia
Grabow, Desiree
Kaatsch, Peter
Kaiser, Melanie
Maule, Milena M.
Jakab, Zsuzsanna
Gunnes, Maria Winther
Terenziani, Monica
Zaletel, Lorna Zadravec
Kuehni, Claudia E.
Haupt, Riccardo
de Vathaire, Florent
Kremer, Leontien C.
Lähteenmäki, Päivi M.
Winther, Jeanette F.
Hjorth, Lars
Hawkins, Michael M.
Reulen, Raoul C.
author_sort Dudley, Isabelle M.
collection PubMed
description BACKGROUND: Survivors of Hodgkin lymphoma (HL) are at risk of developing non‐Hodgkin lymphoma (NHL) after treatment; however, the risks of developing subsequent primary lymphomas (SPLs), including HL and NHL, after different types of childhood cancer are unknown. The authors quantified the risk of SPLs using the largest cohort of childhood cancer survivors worldwide. METHODS: The Pan‐European Network for Care of Survivors After Childhood and Adolescent Cancer (PanCare) Survivor Care and Follow‐Up Studies (PanCareSurFup) cohort includes 69,460 five‐year survivors of childhood cancer, diagnosed during 1940 through 2008, from 12 European countries. Risks of SPLs were quantified by standardized incidence ratios (SIRs) and relative risks (RRs) using multivariable Poisson regression. RESULTS: Overall, 140 SPLs, including 104 NHLs and 36 HLs, were identified. Survivors were at 60% increased risk of an SPL compared with the general population (SIR, 1.6; 95% confidence interval [CI], 1.4–1.9). Survivors were twice as likely to develop NHL (SIR, 2.3; 95% CI, 1.9–2.8), with the greatest risks among survivors of HL (SIR, 7.1; 95% CI, 5.1–10.0), Wilms tumor (SIR, 3.1; 95% CI, 1.7–5.7), leukemia (SIR, 2.8; 95% CI, 1.8–4.4), and bone sarcoma (SIR, 2.7; 95% CI, 1.4–5.4). Treatment with chemotherapy for any cancer doubled the RR of NHL (RR, 2.1; 95% CI, 1.2–3.9), but treatment with radiotherapy did not (RR, 1.2; 95% CI, 0.7–2.0). Survivors were at similar risk of developing a subsequent HL as the general population (SIR, 1.1; 95% CI, 0.8–1.5). CONCLUSIONS: In addition to HL, the authors show here for the first time that survivors of Wilms tumor, leukemia, and bone sarcoma are at risk of NHL. Survivors and health care professionals should be aware of the risk of NHL in these survivors and in any survivors treated with chemotherapy.
format Online
Article
Text
id pubmed-10099796
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-100997962023-04-14 Risk of subsequent primary lymphoma in a cohort of 69,460 five‐year survivors of childhood and adolescent cancer in Europe: The PanCareSurFup study Dudley, Isabelle M. Sunguc, Ceren Heymer, Emma J. Winter, David L. Teepen, Jop C. Belle, Fabiën N. Bárdi, Edit Bagnasco, Francesca Gudmundsdottir, Thorgerdur Skinner, Roderick Michel, Gisela Byrne, Julianne Øfstaas, Hilde Jankovic, Momcilo Mazić, Maja Česen Mader, Luzius Loonen, Jaqueline Garwicz, Stanislaw Wiebe, Thomas Alessi, Daniela Allodji, Rodrigue S. Haddy, Nadia Grabow, Desiree Kaatsch, Peter Kaiser, Melanie Maule, Milena M. Jakab, Zsuzsanna Gunnes, Maria Winther Terenziani, Monica Zaletel, Lorna Zadravec Kuehni, Claudia E. Haupt, Riccardo de Vathaire, Florent Kremer, Leontien C. Lähteenmäki, Päivi M. Winther, Jeanette F. Hjorth, Lars Hawkins, Michael M. Reulen, Raoul C. Cancer Original Articles BACKGROUND: Survivors of Hodgkin lymphoma (HL) are at risk of developing non‐Hodgkin lymphoma (NHL) after treatment; however, the risks of developing subsequent primary lymphomas (SPLs), including HL and NHL, after different types of childhood cancer are unknown. The authors quantified the risk of SPLs using the largest cohort of childhood cancer survivors worldwide. METHODS: The Pan‐European Network for Care of Survivors After Childhood and Adolescent Cancer (PanCare) Survivor Care and Follow‐Up Studies (PanCareSurFup) cohort includes 69,460 five‐year survivors of childhood cancer, diagnosed during 1940 through 2008, from 12 European countries. Risks of SPLs were quantified by standardized incidence ratios (SIRs) and relative risks (RRs) using multivariable Poisson regression. RESULTS: Overall, 140 SPLs, including 104 NHLs and 36 HLs, were identified. Survivors were at 60% increased risk of an SPL compared with the general population (SIR, 1.6; 95% confidence interval [CI], 1.4–1.9). Survivors were twice as likely to develop NHL (SIR, 2.3; 95% CI, 1.9–2.8), with the greatest risks among survivors of HL (SIR, 7.1; 95% CI, 5.1–10.0), Wilms tumor (SIR, 3.1; 95% CI, 1.7–5.7), leukemia (SIR, 2.8; 95% CI, 1.8–4.4), and bone sarcoma (SIR, 2.7; 95% CI, 1.4–5.4). Treatment with chemotherapy for any cancer doubled the RR of NHL (RR, 2.1; 95% CI, 1.2–3.9), but treatment with radiotherapy did not (RR, 1.2; 95% CI, 0.7–2.0). Survivors were at similar risk of developing a subsequent HL as the general population (SIR, 1.1; 95% CI, 0.8–1.5). CONCLUSIONS: In addition to HL, the authors show here for the first time that survivors of Wilms tumor, leukemia, and bone sarcoma are at risk of NHL. Survivors and health care professionals should be aware of the risk of NHL in these survivors and in any survivors treated with chemotherapy. John Wiley and Sons Inc. 2022-11-29 2023-02-01 /pmc/articles/PMC10099796/ /pubmed/36444554 http://dx.doi.org/10.1002/cncr.34561 Text en © 2022 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Dudley, Isabelle M.
Sunguc, Ceren
Heymer, Emma J.
Winter, David L.
Teepen, Jop C.
Belle, Fabiën N.
Bárdi, Edit
Bagnasco, Francesca
Gudmundsdottir, Thorgerdur
Skinner, Roderick
Michel, Gisela
Byrne, Julianne
Øfstaas, Hilde
Jankovic, Momcilo
Mazić, Maja Česen
Mader, Luzius
Loonen, Jaqueline
Garwicz, Stanislaw
Wiebe, Thomas
Alessi, Daniela
Allodji, Rodrigue S.
Haddy, Nadia
Grabow, Desiree
Kaatsch, Peter
Kaiser, Melanie
Maule, Milena M.
Jakab, Zsuzsanna
Gunnes, Maria Winther
Terenziani, Monica
Zaletel, Lorna Zadravec
Kuehni, Claudia E.
Haupt, Riccardo
de Vathaire, Florent
Kremer, Leontien C.
Lähteenmäki, Päivi M.
Winther, Jeanette F.
Hjorth, Lars
Hawkins, Michael M.
Reulen, Raoul C.
Risk of subsequent primary lymphoma in a cohort of 69,460 five‐year survivors of childhood and adolescent cancer in Europe: The PanCareSurFup study
title Risk of subsequent primary lymphoma in a cohort of 69,460 five‐year survivors of childhood and adolescent cancer in Europe: The PanCareSurFup study
title_full Risk of subsequent primary lymphoma in a cohort of 69,460 five‐year survivors of childhood and adolescent cancer in Europe: The PanCareSurFup study
title_fullStr Risk of subsequent primary lymphoma in a cohort of 69,460 five‐year survivors of childhood and adolescent cancer in Europe: The PanCareSurFup study
title_full_unstemmed Risk of subsequent primary lymphoma in a cohort of 69,460 five‐year survivors of childhood and adolescent cancer in Europe: The PanCareSurFup study
title_short Risk of subsequent primary lymphoma in a cohort of 69,460 five‐year survivors of childhood and adolescent cancer in Europe: The PanCareSurFup study
title_sort risk of subsequent primary lymphoma in a cohort of 69,460 five‐year survivors of childhood and adolescent cancer in europe: the pancaresurfup study
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099796/
https://www.ncbi.nlm.nih.gov/pubmed/36444554
http://dx.doi.org/10.1002/cncr.34561
work_keys_str_mv AT dudleyisabellem riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT sungucceren riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT heymeremmaj riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT winterdavidl riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT teepenjopc riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT bellefabienn riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT bardiedit riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT bagnascofrancesca riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT gudmundsdottirthorgerdur riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT skinnerroderick riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT michelgisela riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT byrnejulianne riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT øfstaashilde riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT jankovicmomcilo riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT mazicmajacesen riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT maderluzius riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT loonenjaqueline riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT garwiczstanislaw riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT wiebethomas riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT alessidaniela riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT allodjirodrigues riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT haddynadia riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT grabowdesiree riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT kaatschpeter riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT kaisermelanie riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT maulemilenam riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT jakabzsuzsanna riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT gunnesmariawinther riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT terenzianimonica riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT zaletellornazadravec riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT kuehniclaudiae riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT hauptriccardo riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT devathaireflorent riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT kremerleontienc riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT lahteenmakipaivim riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT wintherjeanettef riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT hjorthlars riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT hawkinsmichaelm riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy
AT reulenraoulc riskofsubsequentprimarylymphomainacohortof69460fiveyearsurvivorsofchildhoodandadolescentcancerineuropethepancaresurfupstudy